Cargando…
Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy
PURPOSE: To evaluate the safety and efficacy of stereotactic body radiation therapy for primary lesion of renal cell carcinoma with long-term and regular follow-up of tumor size and renal function. METHODS: This prospective study included 13 patients treated with stereotactic body radiation therapy...
Autores principales: | Funayama, Satoshi, Onishi, Hiroshi, Kuriyama, Kengo, Komiyama, Takafumi, Marino, Kan, Araya, Masayuki, Saito, Ryo, Aoki, Shinichi, Maehata, Yoshiyasu, Nonaka, Hotaka, Tominaga, Licht, Muramatsu, Juria, Nakagomi, Hiroshi, Kamiyama, Manabu, Takeda, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373992/ https://www.ncbi.nlm.nih.gov/pubmed/30803362 http://dx.doi.org/10.1177/1533033818822329 |
Ejemplares similares
-
Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study
por: Chen, Zhe, et al.
Publicado: (2021) -
Impact of Systemic Autoimmune Diseases on Treatment Outcomes and Radiation Toxicities in Patients with Stage I Non-Small Cell Lung Cancer Receiving Stereotactic Body Radiation Therapy: A Matched Case-Control Analysis
por: Chen, Zhe, et al.
Publicado: (2022) -
Tumor volume shrinkage during stereotactic body radiotherapy is related to better prognoses in patients with stage I non-small-cell lung cancer
por: Vu, Nam, et al.
Publicado: (2020) -
Immune Responses following Stereotactic Body Radiotherapy for Stage I Primary Lung Cancer
por: Maehata, Yoshiyasu, et al.
Publicado: (2013) -
Rib fracture after stereotactic radiotherapy for primary lung cancer: prevalence, degree of clinical symptoms, and risk factors
por: Nambu, Atsushi, et al.
Publicado: (2013)